UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination
- PMID: 36273042
- DOI: 10.1038/s41388-022-02509-1
UBE2O promotes lipid metabolic reprogramming and liver cancer progression by mediating HADHA ubiquitination
Abstract
Cancer cells rely on heightened protein quality control mechanisms, including the ubiquitin-proteosome system that is predominantly driven by ubiquitination comprising E1, E2, and E3 trienzyme cascades. Although E3s have been extensively studied, the implication of E2s in tumorigenesis is poorly defined. Here we reveal a critical E2 in the pathogenesis of hepatocellular carcinoma (HCC). Among all of E2s, UBE2O shows the strongest association with HCC survival prognosis, and its expression is increased in HCC tumors. Accordingly, UBE2O deficiency inhibits HCC growth and metastasis both in vitro and in vivo, while its overexpression has opposite effects. Depending on both E2 and E3 enzymatic activities, UBE2O can interact with and mediate the ubiquitination and degradation of HADHA, a mitochondrial β-oxidation enzyme, thereby modulating lipid metabolic reprogramming. HADHA is reduced in HCC tumors and inversely correlated with UBE2O levels. Importantly, HADHA acts as a tumor suppressor and primarily mediates UBE2O's function on HCC. Moreover, liver-specific deletion of Ube2o in mice are resistant to DEN-induced hepatocarcinogenesis, along with HADHA upregulation and reduced hepatic lipid accumulation. These data reveal UBE2O as a novel oncogenic driver for metabolic reprogramming and HCC development, highlighting the potential of targeting UBE2O/HADHA axis for HCC therapy.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Similar articles
-
UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.Int J Med Sci. 2021 Oct 11;18(16):3749-3758. doi: 10.7150/ijms.63220. eCollection 2021. Int J Med Sci. 2021. PMID: 34790050 Free PMC article.
-
RSK2-mediated phosphorylation and degradation of UBE2O inhibits hepatocellular carcinoma growth and resistance to radiotherapy.Cancer Lett. 2025 Apr 10;615:217558. doi: 10.1016/j.canlet.2025.217558. Epub 2025 Feb 13. Cancer Lett. 2025. PMID: 39954933
-
Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset.FEBS J. 2019 Jun;286(11):2018-2034. doi: 10.1111/febs.14708. Epub 2018 Dec 4. FEBS J. 2019. PMID: 30468556 Review.
-
MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming.J Hematol Oncol. 2020 Feb 7;13(1):12. doi: 10.1186/s13045-019-0841-3. J Hematol Oncol. 2020. PMID: 32033570 Free PMC article.
-
New Insights into the Role of E2s in the Pathogenesis of Diseases: Lessons Learned from UBE2O.Mol Cells. 2018 Mar 31;41(3):168-178. doi: 10.14348/molcells.2018.0008. Epub 2018 Mar 20. Mol Cells. 2018. PMID: 29562734 Free PMC article. Review.
Cited by
-
Enhanced nuclear translation is associated with proliferation and progression across multiple cancers.MedComm (2020). 2023 Apr 14;4(3):e248. doi: 10.1002/mco2.248. eCollection 2023 Jun. MedComm (2020). 2023. PMID: 37063610 Free PMC article.
-
Fasting: From Physiology to Pathology.Adv Sci (Weinh). 2023 Mar;10(9):e2204487. doi: 10.1002/advs.202204487. Epub 2023 Feb 3. Adv Sci (Weinh). 2023. PMID: 36737846 Free PMC article. Review.
-
The role of ubiquitination and deubiquitination in cancer lipid metabolism.Front Oncol. 2025 Jan 29;15:1464914. doi: 10.3389/fonc.2025.1464914. eCollection 2025. Front Oncol. 2025. PMID: 39944823 Free PMC article. Review.
-
F-box only protein 2 exacerbates non-alcoholic fatty liver disease by targeting the hydroxyl CoA dehydrogenase alpha subunit.World J Gastroenterol. 2023 Jul 28;29(28):4433-4450. doi: 10.3748/wjg.v29.i28.4433. World J Gastroenterol. 2023. PMID: 37576703 Free PMC article.
-
HADHA promotes esophageal cancer progression by activating mTOR signaling and the SP1/MDM2 axis.Acta Biochim Biophys Sin (Shanghai). 2024 Sep 26;57(3):378-388. doi: 10.3724/abbs.2024139. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 39327932 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous